cefsulodin

Cefsulodin is a third-generation cephalosporin antibiotic with a narrow antibacterial spectrum, primarily active against *Pseudomonas aeruginosa* and some activity against *Staphylococcus aureus*, but little to no significant activity against other Gram-negative bacteria, Gram-positive bacteria, or anaerobes[1][3][4][5]. It was discovered by Takeda Pharmaceutical Company in 1977[1]. The drug is resistant to hydrolysis by many β-lactamases produced by Gram-negative bacilli. Its mechanism of action involves inhibition of bacterial cell wall synthesis through competitive inhibition of penicillin binding proteins (PBPs), which are essential for the final phase of peptidoglycan cross-linking in the bacterial cell wall[6][8]. Clinically, it has been used for systemic infections caused by *Pseudomonas aeruginosa* and is administered parenterally (IV or IM)[4][5]. It also finds use in selective media (CIN agar) for isolating *Yersinia enterocolitica* from environmental samples[1][6].

Brand names

CefonomilPseudomonilPyocefalMonasporPseudocefTakesulinTilmapor

Other names

CefsulodineCefsulodinumCefsulodino